MEDEXUS PHARMACEUTICALS INC (MDP.CA) Fundamental Analysis & Valuation

TSX:MDP • CA58410Q2036

Current stock price

3.14 CAD
+0.11 (+3.63%)
Last:

This MDP.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. MDP.CA Profitability Analysis

1.1 Basic Checks

  • In the past year MDP has reported negative net income.
  • In the past year MDP had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: MDP reported negative net income in multiple years.
  • In multiple years MDP reported negative operating cash flow during the last 5 years.
MDP.CA Yearly Net Income VS EBIT VS OCF VS FCFMDP.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M -10M 20M -20M

1.2 Ratios

  • MDP has a Return On Assets of -0.18%. This is in the better half of the industry: MDP outperforms 70.59% of its industry peers.
  • Looking at the Return On Equity, with a value of -0.52%, MDP is in the better half of the industry, outperforming 70.59% of the companies in the same industry.
  • MDP has a Return On Invested Capital of 3.02%. This is in the better half of the industry: MDP outperforms 70.59% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for MDP is in line with the industry average of 8.22%.
  • The 3 year average ROIC (9.89%) for MDP is well above the current ROIC(3.02%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -0.18%
ROE -0.52%
ROIC 3.02%
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
MDP.CA Yearly ROA, ROE, ROICMDP.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150

1.3 Margins

  • With a decent Operating Margin value of 3.91%, MDP is doing good in the industry, outperforming 73.53% of the companies in the same industry.
  • MDP has a better Gross Margin (53.87%) than 82.35% of its industry peers.
  • MDP's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 3.91%
PM (TTM) N/A
GM 53.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
MDP.CA Yearly Profit, Operating, Gross MarginsMDP.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. MDP.CA Health Analysis

2.1 Basic Checks

  • MDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, MDP has more shares outstanding
  • MDP has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, MDP has an improved debt to assets ratio.
MDP.CA Yearly Shares OutstandingMDP.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
MDP.CA Yearly Total Debt VS Total AssetsMDP.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of 0.65, we must say that MDP is in the distress zone and has some risk of bankruptcy.
  • MDP has a Altman-Z score of 0.65. This is in the better half of the industry: MDP outperforms 64.71% of its industry peers.
  • The Debt to FCF ratio of MDP is 1.48, which is an excellent value as it means it would take MDP, only 1.48 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 1.48, MDP belongs to the top of the industry, outperforming 91.18% of the companies in the same industry.
  • MDP has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.35, MDP is in line with its industry, outperforming 52.94% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 1.48
Altman-Z 0.65
ROIC/WACC0.33
WACC9.27%
MDP.CA Yearly LT Debt VS Equity VS FCFMDP.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

2.3 Liquidity

  • MDP has a Current Ratio of 1.12. This is a normal value and indicates that MDP is financially healthy and should not expect problems in meeting its short term obligations.
  • MDP has a Current ratio of 1.12. This is in the lower half of the industry: MDP underperforms 79.41% of its industry peers.
  • A Quick Ratio of 0.62 indicates that MDP may have some problems paying its short term obligations.
  • MDP has a worse Quick ratio (0.62) than 79.41% of its industry peers.
Industry RankSector Rank
Current Ratio 1.12
Quick Ratio 0.62
MDP.CA Yearly Current Assets VS Current LiabilitesMDP.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. MDP.CA Growth Analysis

3.1 Past

  • MDP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -112.14%.
  • Looking at the last year, MDP shows a decrease in Revenue. The Revenue has decreased by -9.23% in the last year.
  • The Revenue has been growing slightly by 7.82% on average over the past years.
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%

3.2 Future

  • MDP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.29% yearly.
  • The Revenue is expected to grow by 10.80% on average over the next years. This is quite good.
EPS Next Y-112.62%
EPS Next 2Y101%
EPS Next 3Y109.18%
EPS Next 5Y53.29%
Revenue Next Year-8.18%
Revenue Next 2Y2.38%
Revenue Next 3Y8.11%
Revenue Next 5Y10.8%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MDP.CA Yearly Revenue VS EstimatesMDP.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M 200M
MDP.CA Yearly EPS VS EstimatesMDP.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 -1

More info and screens

Find the best growth stocksShow best growing peers

6

4. MDP.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MDP. In the last year negative earnings were reported.
  • Based on the Price/Forward Earnings ratio of 7.14, the valuation of MDP can be described as very cheap.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of MDP indicates a rather cheap valuation: MDP is cheaper than 88.24% of the companies listed in the same industry.
  • MDP is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.84, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 7.14
MDP.CA Price Earnings VS Forward Price EarningsMDP.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150

4.2 Price Multiples

  • 85.29% of the companies in the same industry are more expensive than MDP, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of MDP indicates a rather cheap valuation: MDP is cheaper than 91.18% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 4.35
EV/EBITDA 6.05
MDP.CA Per share dataMDP.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

  • MDP's earnings are expected to grow with 109.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y101%
EPS Next 3Y109.18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDP.CA Dividend Analysis

5.1 Amount

  • No dividends for MDP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MDP.CA Fundamentals: All Metrics, Ratios and Statistics

MEDEXUS PHARMACEUTICALS INC

TSX:MDP (3/13/2026, 7:00:00 PM)

3.14

+0.11 (+3.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11
Earnings (Next)N/A
Inst Owners0.65%
Inst Owner ChangeN/A
Ins Owners7.65%
Ins Owner ChangeN/A
Market Cap101.42M
Revenue(TTM)99.43M
Net Income(TTM)-272.00K
Analysts82.5
Price Target7.03 (123.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.21%
Min EPS beat(2)0.99%
Max EPS beat(2)107.43%
EPS beat(4)4
Avg EPS beat(4)77.72%
Min EPS beat(4)0.99%
Max EPS beat(4)144%
EPS beat(8)7
Avg EPS beat(8)78.39%
EPS beat(12)9
Avg EPS beat(12)100.87%
EPS beat(16)11
Avg EPS beat(16)73.38%
Revenue beat(2)0
Avg Revenue beat(2)-2.26%
Min Revenue beat(2)-4.22%
Max Revenue beat(2)-0.29%
Revenue beat(4)0
Avg Revenue beat(4)-1.39%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)-0.29%
Revenue beat(8)2
Avg Revenue beat(8)-0.34%
Revenue beat(12)4
Avg Revenue beat(12)-1.11%
Revenue beat(16)7
Avg Revenue beat(16)0.69%
PT rev (1m)11.09%
PT rev (3m)11.47%
EPS NQ rev (1m)50%
EPS NQ rev (3m)50%
EPS NY rev (1m)85.71%
EPS NY rev (3m)81.82%
Revenue NQ rev (1m)0.82%
Revenue NQ rev (3m)1.21%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)-0.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.14
P/S 0.75
P/FCF 4.35
P/OCF 4.29
P/B 1.43
P/tB N/A
EV/EBITDA 6.05
EPS(TTM)-0.02
EYN/A
EPS(NY)0.44
Fwd EY14%
FCF(TTM)0.72
FCFY23.01%
OCF(TTM)0.73
OCFY23.29%
SpS4.19
BVpS2.2
TBVpS-0.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.18%
ROE -0.52%
ROCE 4.2%
ROIC 3.02%
ROICexc 3.61%
ROICexgc 107.26%
OM 3.91%
PM (TTM) N/A
GM 53.87%
FCFM 17.26%
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 1.48
Debt/EBITDA 1.33
Cap/Depr 2.1%
Cap/Sales 0.21%
Interest Coverage 1.57
Cash Conversion 127.65%
Profit Quality N/A
Current Ratio 1.12
Quick Ratio 0.62
Altman-Z 0.65
F-Score5
WACC9.27%
ROIC/WACC0.33
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y-112.62%
EPS Next 2Y101%
EPS Next 3Y109.18%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%
Revenue Next Year-8.18%
Revenue Next 2Y2.38%
Revenue Next 3Y8.11%
Revenue Next 5Y10.8%
EBIT growth 1Y-74.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year73.75%
EBIT Next 3Y62.94%
EBIT Next 5Y44.59%
FCF growth 1Y-17.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.2%
OCF growth 3YN/A
OCF growth 5YN/A

MEDEXUS PHARMACEUTICALS INC / MDP.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to MDP.CA.


What is the valuation status of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?

ChartMill assigns a valuation rating of 6 / 10 to MEDEXUS PHARMACEUTICALS INC (MDP.CA). This can be considered as Fairly Valued.


Can you provide the profitability details for MEDEXUS PHARMACEUTICALS INC?

MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a profitability rating of 5 / 10.


What is the financial health of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?

The financial health rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 4 / 10.